drugset / Trial / NCT02245724

Stem Cell Therapy in Mental Retardation

NCT02245724

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.

Timeline

Start
2011-09
Primary completion
2016-03
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy Intrathecal

Indications

No indication recorded.